Oncimmune Holdings PLC - Leeds, England-based autoantibody profiling research services to pharmaceutical and biotechnology industry to enable delivery of precision medicine - Reiterates it expects to report revenue of around £3 million for the financial year ended August 31, surged from £1.2 million a year prior. However, notes that since the end of October, one potential contract was deferred into financial year 2026, and one was removed from its pipeline.

For financial 2025, the firm expects revenue of around £4 million, up 33% from financial 2024.

‘In line with the rest of the Pharma services outsourcing market, conversion of new contracts has been slower than since late 2024. At the same time as vigorously pursuing follow-on work, Oncimmune is discussing a number of significant strategic collaborations and transformative contracts with several parties which, whilst there is no certainty, could materially improve its revenue position in FY2025,’ the company says.

Current stock price: 9.90 pence each, down 20% on Friday morning in London

12-month change: down 61%

Copyright 2025 Alliance News Ltd. All Rights Reserved.